With the purpose to evaluate the therapeutic potential of ECFC-MMP12 for melanoma growth in vivo, a mixture of 1×106 viable A375 and 0.5x106 MSCs were co-injected into 6 to 8 weeks old CD-1 nude (nu/nu) mice together with 0.5x106 ECFC-MMP12 or ECFC-MOCK. Here, MMP12 is linked to melanoma.